articles and announcements

megan-gloeckner

February 5, 2020

megan-gloeckner

Community Advisory Board
First Patient(s) Dosed in Ultragenyx Phase 3 Aspire Study
Ionis Releases News about Clinical Trial of ION582
Neuren Releases Results from Phase 2 Clinical Trial of NNZ-2591
Ionis Releases Data from the Phase 1/2 Halos Clinical Trial
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA
Researchers at UNC Chapel Hill Find New Potential Treatment for AS
Dubai Launches First Angelman Clinic in GCC
Ionis Announces Positive Results from Halos Phase 1/2a
Ultragenyx Announces Positive Interim Phase 1/2 Data from GTX-102
Family Advocates Urge Congress’ Support During Inaugural Angelman Syndrome (AS) Congressional Advocacy Day
Angelman Clinic opens at Cedars-Sinai Guerin Children’s
Angelman Clinic opens at Children’s Hospital of Philadelphia (CHOP)
ASF and .PROT partner to launch new Angelman Center for families in Poland
Roche Clinical Trial of Rugonersen in Angelman Syndrome
ASF Opens Application for its Inaugural Jacob Pritzker Fellowship
Canadian Angelman Syndrome Society is now ASF Canada
GFAS Ukraine and ASF partner to Launch Clinic in Ukraine
Health Issues in Adults with Angelman Syndrome
AngelmanUK and ASF partner to launch clinics in the UK

Browse

What is Angelman Syndrome
For Parents
ASF Funded Research
Make an Impact
Events
About
Angelman Resources & Education
Contact Registry
News

Address Angelman Syndrome Foundation
3015 E. New York Street
Suite A2-#285
Aurora, IL 60504 Phone800.432.6435 Emailinfo@angelman.org

Connect

facebook
twitter
linkedin
instagram
pinterest
rss
youtube

The Mission

The mission of the Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.